Greenwich LifeSciences Inc (GLSI)
14.95
+1.54
(+11.48%)
USD |
NASDAQ |
May 31, 16:00
15.12
+0.17
(+1.14%)
After-Hours: 20:00
Greenwich LifeSciences Enterprise Value: 187.05M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 187.05M |
| May 30, 2024 | 167.21M |
| May 29, 2024 | 164.12M |
| May 28, 2024 | 164.38M |
| May 24, 2024 | 167.09M |
| May 23, 2024 | 162.96M |
| May 22, 2024 | 168.37M |
| May 21, 2024 | 168.89M |
| May 20, 2024 | 162.96M |
| May 17, 2024 | 174.56M |
| May 16, 2024 | 180.61M |
| May 15, 2024 | 184.47M |
| May 14, 2024 | 170.18M |
| May 13, 2024 | 162.71M |
| May 10, 2024 | 171.59M |
| May 09, 2024 | 174.94M |
| May 08, 2024 | 170.56M |
| May 07, 2024 | 170.03M |
| May 06, 2024 | 173.12M |
| May 03, 2024 | 179.81M |
| May 02, 2024 | 174.66M |
| May 01, 2024 | 174.79M |
| April 30, 2024 | 154.44M |
| April 29, 2024 | 156.76M |
| April 26, 2024 | 163.46M |
| Date | Value |
|---|---|
| April 25, 2024 | 153.41M |
| April 24, 2024 | 157.02M |
| April 23, 2024 | 163.72M |
| April 22, 2024 | 157.92M |
| April 19, 2024 | 149.94M |
| April 18, 2024 | 160.50M |
| April 17, 2024 | 162.56M |
| April 16, 2024 | 180.20M |
| April 15, 2024 | 178.14M |
| April 12, 2024 | 196.04M |
| April 11, 2024 | 201.32M |
| April 10, 2024 | 198.36M |
| April 09, 2024 | 208.61M |
| April 08, 2024 | 206.29M |
| April 05, 2024 | 218.27M |
| April 04, 2024 | 225.61M |
| April 03, 2024 | 222.64M |
| April 02, 2024 | 219.68M |
| April 01, 2024 | 239.64M |
| March 28, 2024 | 249.20M |
| March 27, 2024 | 249.97M |
| March 26, 2024 | 254.09M |
| March 25, 2024 | 242.91M |
| March 22, 2024 | 245.09M |
| March 21, 2024 | 236.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
35.55M
Minimum
Nov 13 2020
861.81M
Maximum
Dec 10 2020
229.61M
Average
162.19M
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 803.37B |
| Outlook Therapeutics Inc | 162.76M |
| Gain Therapeutics Inc | 33.88M |
| CEL-SCI Corp | 60.22M |
| AIM ImmunoTech Inc | 10.88M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.473M |
| Total Expenses (Quarterly) | 2.537M |
| EPS Diluted (Quarterly) | -0.19 |
| Earnings Yield | -4.82% |